NEW YORK, April 4, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community. Todaywe are offering reports on LPCN, AKRX, COLL, and HZNP which can be accessed for free by signing up to www.wallstequities.com/registration. Today, WallStEquities.com scans Lipocine Inc. (NASDAQ: LPCN), Akorn Inc. (NASDAQ: AKRX), Collegium Pharmaceutical
Salt Lake City, Utah headquartered Lipocine Inc.'s shares declined slightly by 0.66%, closing Tuesday's trading session at $1.50. The stock recorded a trading volume of 115,169 shares. The Company's shares are trading 4.59% above their 50-day moving average. Additionally, shares of Lipocine, which develops pharmaceutical products using its oral drug delivery technology in the areas of men's and women's health, have a Relative Strength Index (RSI) of 48.71.
On March 12th, 2018, Lipocine announced its financial results for the fiscal year ended December 31st, 2017. Net loss for the full year was $21.0 million, research and development expenses were $11.0 million, and general and administrative expenses were $10.2 million. As of December 31st, 2017, the Company had cash, cash equivalents, and marketable securities of $21.5 million. Get the full research report on LPCN for free by clicking below at:
On Tuesday, shares in Lake Forest, Illinois headquartered Akorn Inc. recorded a trading volume of 1.30 million shares. The stock rose 2.31%, ending the day at $19.07. The Company's shares have advanced 0.53% in the past month. The stock is trading below its 50-day moving average by 25.28%. Furthermore, shares of Akorn, which develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter consumer health products, and animal health pharmaceuticals in the US and internationally, have an RSI of 33.85. AKRX's complimentary research coverage is a few simple steps away at:
Canton, Massachusetts headquartered Collegium Pharmaceutical Inc.'s stock finished the day 2.28% higher at $24.18 with a total trading volume of 589,394 shares. The Company's shares have advanced 30.99% in the previous three months and 140.36% over the past year. The stock is trading above its 200-day moving average by 50.39%. Additionally, shares of Collegium Pharma, which develops and commercializes various products for patients suffering from pain, have an RSI of 43.75.
On March 08th, 2018, research firm H.C. Wainwright reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $21 a share to $33 a share. Register for your free research report on COLL at:
Shares in Dublin, Ireland headquartered Horizon Pharma PLC ended yesterday's session 1.16% higher at $13.96. The stock recorded a trading volume of 1.90 million shares, which was above its three months average volume of 1.83 million shares. The Company's shares are trading 2.01% above their 200-day moving average. Moreover, shares of Horizon Pharma, which focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the US and internationally, have an RSI of 40.72. Wall St. Equities' downloadable research report on HZNP available at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: email@example.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/this-mornings-technical-outlook-on-generic-drugs-stocks----lipocine-akorn-collegium-pharma-and-horizon-pharma-300624183.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!